A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects

Inclusion criteria

• Healthy Chinese subjects between 18 and 55 years old (inclusive) at Screening
• Free of any clinically significant disease or medical condition at screening as determinedby the Investigator
• Body weight ≥ 50 kg (110 lbs) and a body mass index ≥ 18 and ≤ 32 kg/m2
• Women must be of non-childbearing potential:Surgically sterile; no menses for ≥ 12 months AND a follicle-stimulating hormone level>40 IU/L at screening; or meeting the definition of "postmenopausal range" based onscreening laboratory results
• Willing and able to comply with all the study requirements and provide written informedconsent for the study

Exclusion criteria

• Donated blood or experienced significant blood loss
• Has inadequate venous access or unsuitable veins for venipuncture and IV administrationof the study drug
• History of or have any evidence of diabetes mellitus
• History of renal impairment or inflammatory bowel disease
• History of clinically significant ear pathology, ear surgery, or hearing impairment
• Active infection
• History of malignancy
• Have undergone a surgical procedure within 3 months prior to study entry or have anysurgical procedure anticipated to be required during the study.
• Any clinically significant abnormality at screening that, inthe opinion of the Investigator, would exclude them from the study
• Received the last dose of an investigational drug or treatment with a medical devicewithin 30 days or 5 half-lives prior to screening or currentlyparticipating in another study of an investigational drug or medical device
• Previously participated in a study of IGF-1 or IGF-1R-related products
• Any medical condition or laboratory abnormality, that in the opinion of the Investigator, would prevent the subject from completing the study, pose a risk to the subject, or confound the ability to interpret study results